Research Topics
Genomes and Genes | Powel H BrownSummaryAffiliation: Baylor College of Medicine Country: USA Publications
| Collaborators
|
Detail Information
Publications
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in miceTracy E Strecker
Breast Center, Department of Medicine and Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
J Natl Cancer Inst 101:107-13. 2009..Thus, cyclin D1, epiregulin, and p27 may represent useful biomarkers of lapatinib response in patients. These data suggest that lapatinib is a promising agent for the prevention of ER-negative breast cancer...- Conference Report: Seventh Annual AACR International Conference on Frontiers in Cancer Prevention ResearchPowel H Brown
Baylor College of Medicine, Houston, Texas 77030, USA
Cancer Prev Res (Phila) 2:995-8. 2009..These and the other presentations at this meeting continue to provide strong support for the concept that cancer will be most effectively controlled by applying modern cancer prevention strategies... - SLC22A5/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE)Chunyu Wang
Department of Clinical Cancer Prevention, M D Anderson Cancer Center, Houston, TX 77030, USA
Breast Cancer Res Treat 134:101-15. 2012..Since SLC22A5 is a critical regulator of carnitine homeostasis, lipid metabolism, and cell proliferation, SLC22A5 may serve as a potential therapeutic target for breast cancer in the future... 
The combination of tamoxifen and the rexinoid LG100268 prevents ER-positive and ER-negative mammary tumors in p53-null mammary gland miceAbhijit Mazumdar
Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Cancer Prev Res (Phila) 5:1195-202. 2012..These results support the development of clinical trials of antiestrogen and rexinoid combinatorial therapy for the prevention of patients with high-risk breast cancer...- The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressorYuxin Li
Department of Clinical Cancer Prevention, The University of Texas, Anderson Cancer Center Cancer, Houston, TX 77030, USA
Breast Cancer Res Treat 128:667-77. 2011..By elucidating the mechanism by which rexinoids inhibit cell proliferation, it will be possible to develop more effective and less toxic drugs to prevent ER-negative breast cancers... - The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cellsChunyu Wang
Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Breast Cancer Res Treat 133:487-500. 2012..Taken together, our study suggests that RET/PTC kinase may serve as a novel prognostic biomarker and therapeutic target for prevention and treatment of ER-positive breast cancer... - Cancer-preventive rexinoid modulates neutral lipid contents of mammary epithelial cells through a peroxisome proliferator-activated receptor γ-dependent mechanismIvan P Uray
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
Mol Pharmacol 81:228-38. 2012.... - Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factorChunyu Wang
Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Mol Endocrinol 25:1527-38. 2011..These results solve the long-standing question in the field of endocrinology of how estrogen induces c-myc expression... - Aromatase inhibitors and breast cancer preventionJennifer Keating Litton
The University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA
Expert Opin Pharmacother 13:325-31. 2012..We continue to await further follow-up on exemestane as well as other aromatase inhibitors in the prevention setting for women at high risk of developing breast cancer or with a history of ductal carcinoma in situ... - Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cellsLu Chen
Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
Cancer Res 69:8853-61. 2009..Because most ER-negative breast tumors express mutant p53, our results provide the foundation for future development of p38 inhibitors to target p38 for the treatment of p53 mutant and ER-negative breast cancers... - Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxibDaniel Medina
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA
Cancer Prev Res (Phila) 2:168-74. 2009.... - Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1Ivan P Uray
Breast Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
J Biol Chem 284:345-53. 2009..These results demonstrate a novel cooperative interaction between retinoid receptors and AP-1 orchestrated by RARbeta and highlight a novel mechanism by which RARbeta can mediate the cancer-preventive effects of rexinoids... - Chemoprevention of hormone receptor-negative breast cancer: new approaches neededIvan P Uray
Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
Recent Results Cancer Res 188:147-62. 2011..It is anticipated that in the future these molecularly targeted drugs will be combined with hormonal agents such as SERMs or aromatase inhibitors to prevent all forms of breast cancer... - Two good choices to prevent breast cancer: great taste, less fillingGabriel N Hortobagyi
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
Cancer Prev Res (Phila) 3:681-5. 2010..For 12 years, the public has avoided Food and Drug Administration-approved tamoxifen or raloxifene for breast cancer risk reduction; it is time to reemphasize the great preventive benefit of these agents to the public... 
The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemopreventionGu Kong
Breast Center, Departments of Medicine and Molecular and Cellular Biology, Baylor College of Medicine, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Cancer Res 65:3462-9. 2005..Furthermore, such RXR-selective retinoids may be most useful in combination with antiestrogens for more effective prevention of breast cancer in women at high risk of this disease...- Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069Kendall Wu
Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
Cancer Epidemiol Biomarkers Prev 11:467-74. 2002.... - The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic miceKendall Wu
Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
Cancer Res 62:6376-80. 2002..These studies suggest that receptor-selective retinoids are promising agents for the prevention of breast cancer and that they may be particularly useful in preventing ER-negative breast cancer... - A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesisRobert K Dearth
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
BMC Cancer 11:377. 2011..The purpose of this study was to assess the ability of circulating IGF-I to independently initiate mammary tumorigenesis and/or accelerate the progression of ErbB2 mediated mammary tumor growth... - A novel look into estrogen receptor-negative breast cancer prevention with the natural, multifunctional signal transduction inhibitor deguelinJennifer M Rodenberg
Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
Cancer Prev Res (Phila) 2:915-8. 2009..Our growing understanding of deguelin mechanisms could lead to important advances in the prevention of estrogen receptor-negative breast and other cancers... - Tumor-suppressor activity of RRIG1 in breast cancerGuihong Zhang
Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
BMC Cancer 11:32. 2011..The aim of this study was to determine whether RRIG1 plays a role in breast cancer, such as in the suppression of breast cancer cell growth and invasion... - Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumorsChunhua Lu
Department of Medicine, Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
J Natl Cancer Inst 95:1825-33. 2003..We examined whether ZD1839 blocks signal transduction and prevents the development of ER-negative breast cancer... - Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoidPowel H Brown
Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
Cancer Prev Res (Phila) 1:208-14. 2008..Our data show that simultaneous blockade of COX/prostaglandin signaling and retinoid X receptor-dependent transcription confers potent anticancer efficacy, suggesting a novel avenue for clinical evaluation... - Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention ResearchAshraful Hoque
Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
Cancer Res 67:8989-93. 2007.... - Transgenic mouse models for the prevention of breast cancerQiang Shen
Breast Center, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
Mutat Res 576:93-110. 2005..However, many barriers to progress must be overcome, including access to and availability of new cancer preventive drugs, and difficulties in conducting studies of combinations of preventive agents... - Prevention of breast cancer: current state of the science and future opportunitiesIvan P Uray
Breast Care Center, Department of Medicine, Baylor College of Medicine, Methodist Hospital, Houston, TX 77030, USA
Expert Opin Investig Drugs 15:1583-600. 2006..In the future, hormonal and estrogen receptor-independent agents may be combined to prevent the development of all mammary tumours. This article reviews the current and novel strategies for breast cancer prevention... - Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arraysHee-Tae Kim
Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
Cancer Res 66:12009-18. 2006..These critical growth-regulating proteins will be promising targets of future agents for the prevention and treatment of breast cancer... - Translational approaches for the prevention of estrogen receptor-negative breast cancerYuxin Li
Departments of Medicine and Molecular and Cellular Biology, Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
Eur J Cancer Prev 16:203-15. 2007..We also discuss the promise of combining these agents for the effective prevention of all forms of breast cancer... - The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 miceYuxin Li
Breast Center, Department of Medicine, Baylor College of Medicine, Houston TX 77030, USA
Clin Cancer Res 13:6224-31. 2007..To test whether a novel rexinoid, LG100268, prevents the development of preinvasive and invasive estrogen receptor-negative mammary tumorigenesis in MMTV-erbB2 mice... - The AP-1 transcription factor regulates postnatal mammary gland developmentQiang Shen
Breast Center, Baylor College of Medicine, MS600, 1 Baylor Plaza, Houston, TX 77030, USA
Dev Biol 295:589-603. 2006..We therefore conclude that AP-1 factor is a pivotal regulator of postnatal mammary gland growth and development... - Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathwaysQiang Shen
Breast Center, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA
J Mammary Gland Biol Neoplasia 8:45-73. 2003..The chemopreventive activity of these agents and other novel signal transduction inhibitors are discussed in this chapter... - Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs)Rachel Schiff
The Breast Center, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
Breast Cancer Res 5:228-31. 2003..Two recent studies in preclinical model systems that evaluate mechanisms of action of these new drugs and suggestions about their optimal clinical use are discussed... - Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumorsQiang Shen
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
Cancer Prev Res (Phila) 1:45-55. 2008..These results provide a scientific rationale to develop targeted drugs that inhibit AP-1 to prevent the development of ER-negative breast cancer...